# ARROWHEAD PHARMACEUTICALS, INC. (ARWR) · Edgar & Edgarette company card

> Arrowhead Pharmaceuticals (ARWR) grew revenue 23258% in FY2025 to $829 million, operating margin 11.9% against a -3.8% median for pharmaceutical preparations, equity 33.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 879407 · fiscal year ended 2025-09-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/ARWR) · [JSON](https://www.pops4.com/boards/company/ARWR.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $829M |
| Revenue growth, 1 year | 23258.2% |
| Revenue growth per year | 56.5% |
| Operating margin | 11.9% (prior year -16927.1%) |
| Net margin | 3.6% |
| Operating cash flow | $180M |
| Capital spending | $23M |
| Free cash flow | $157M |
| Cash | $227M |
| Long-term debt | — |
| Total assets | $1.4B |
| Total equity | $466M |
| Equity ÷ assets | 33.6% |
| Return on equity | 6.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 0.76 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Health Harbor boat: Sound ship · one warning sign · revenue is hard to predict: its 80% range is ±35%
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $829.4M (FY2025). Experience: revenue up 23258.2% on the year, up 56.5% a year over 4 years; operating margin 11.9%, up from -16927.1%. Soundness: equity 33.6% of assets, return on equity 6.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $66.7B and $138.0B next year (method v4.1: its own 2-year record of growth weighed at 25% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $55.5B to $167.1B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 11.9% against a -3.8% median; growth 23258.2% against 13.7%.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-06-16 ([filing](https://www.sec.gov/Archives/edgar/data/879407/000087940726000050/0000879407-26-000050-index.htm))

## Recent filings

- 8-K · filed 2026-11-04 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation · [filing](https://www.sec.gov/Archives/edgar/data/879407/000087940726000063/0000879407-26-000063-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/879407/000087940726000058/0000879407-26-000058-index.htm)
- 10-Q · filed 2026-08-04 · [filing](https://www.sec.gov/Archives/edgar/data/879407/000087940726000057/0000879407-26-000057-index.htm)
- 8-K · filed 2026-06-16 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/879407/000087940726000050/0000879407-26-000050-index.htm)
- 10-Q · filed 2026-05-07 · [filing](https://www.sec.gov/Archives/edgar/data/879407/000087940726000047/0000879407-26-000047-index.htm)
- 8-K · filed 2026-05-07 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/879407/000087940726000045/0000879407-26-000045-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000879407.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=879407

## Cite

POPS4, Edgar & Edgarette: ARROWHEAD PHARMACEUTICALS, INC. (ARWR) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/ARWR. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.